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Available online 11 December 2015Peroxisomes contain numerous enzymatic activities that are important for mammalian physiology. Patients lacking
either all peroxisomal functions or a single enzymeor transporter function typically develop severe neurological def-
icits, which originate from aberrant development of the brain, demyelination and loss of axonal integrity, neuroin-
ﬂammation or other neurodegenerative processes. Whilst correlating peroxisomal properties with a compilation of
pathologies observed in human patients andmousemodels lacking all or individual peroxisomal functions, we dis-
cuss the importance of peroxisomal metabolites and tissue- and cell type-speciﬁc contributions to the observed
brain pathologies. This enables us to deconstruct the local and systemic contribution of individual metabolic path-
ways to speciﬁc brain functions. We also review the recently discovered variability of pathological symptoms in
caseswith unexpectedlymild presentation of peroxisomebiogenesis disorders. Finally,we explore the emerging ev-
idence linking peroxisomes tomore common neurological disorders such as Alzheimer's disease, autism and amyo-
trophic lateral sclerosis. This article is part of a Special Issue entitled: Peroxisomes edited by Ralf Erdmann.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Peroxisomes are single membrane-bound organelles, which harbor
a variety of biochemical reactions andmetabolic pathways that contrib-
ute to different physiological functions in eukaryotic organisms. Perox-
isomes are found ubiquitously, but their number, shape and enzymatic
content appear variable and differ between organisms and tissues and
even upon changes in the environment [1]. In this review, we restrict
the discussion to peroxisomal functions in the mammalian nervous
system,with a speciﬁc focus on human physiology and pathophysiology
supplemented by observations made in various mouse models. In
mammals, peroxisomes contain around 50 different proteins [2],
which exert a variety of catabolic and anabolic reactions as, for example,
the degradation of very long-chain fatty acids (VLCFA)1, dicarboxylicmes edited by Ralf Erdmann.
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phospholipids or speciﬁc polyunsaturated fatty acids [3].
The importance of peroxisomes for mammalian physiology is
highlighted by the existence of a variety of severe inherited human
diseases caused by the complete or partial loss of peroxisomal func-
tions. These diseases have been subdivided into peroxisome biogene-
sis disorders (PBD), in which the formation of functional peroxisomes
is disturbed, and single enzyme and transporter deﬁciencies lacking in-
dividual enzymatic activities that are performed by peroxisomes. Pa-
tients suffering from PBD show a broad spectrum of symptoms
summarized as Zellweger spectrum disorders and rhizomelic
chondrodysplasia punctata (RCDP) type 1. The genetic basis for
each PBD is amutation in one of 14 PEX genes, which encode proteins
termed peroxins (PEX proteins or peroxisome biogenesis factors),
which are involved in the biogenesis of the organelle (Table 1). All
peroxisomal enzymes and membrane proteins contain a targeting
signal, which is necessary and sufﬁcient to mediate the interaction
of the encoding protein with a receptor protein that translocates its
cargo to peroxisomes and initiates the import. These processes are
carried out by the PEX proteins (Fig. 1), which are either involved
in the import of matrix proteins (PEX1, 2, 5, 6, 7, 10, 12, 13, 14, 26)
or of membrane proteins (PEX3, 16 and 19) [4]. Soluble proteins har-
bor such peroxisome targeting signal (PTS) sequences either at their
extreme C-terminus (type 1, PTS1) or close to their N-terminus (type
2, PTS2), whereas membrane proteins contain targeting signals for
membrane proteins (mPTS). PTS1 is required for the interaction
with the cytoplasmic receptor PEX5, PTS2 for the interaction with
PEX7 and the mPTS for the interaction with PEX19. This is the reason
why in Zellweger spectrum patients, on the cellular level, peroxi-
somes are either absent or empty (ghosts).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Genetic basis of peroxisomal disorders.
Gene Protein Disease Phenotype
MIM
Reference
Peroxisome biogenesis disorders
Zellweger syndrome spectrum disorder
PEX1 Peroxin 1 (PEX1) Zellweger syndrome,
neonatal adrenoleukodystrophy, infantile Refsum disease
214100
601539
[316]
PEX2 Peroxin 2 (PEX2) Zellweger syndrome,
infantile Refsum disease
614866
614867
[46]
[317]
PEX3 Peroxin 3 (PEX3) Zellweger syndrome 614882 [318]
PEX5 Peroxin 5 (PEX5) Zellweger syndrome,
neonatal adrenoleukodystrophy
214110
202370
[319]
PEX6 Peroxin 6 (PEX6) Zellweger syndrome,
neonatal adrenoleukodystrophy, infantile Refsum disease
614862
614863
[320]
[321]
PEX10 Peroxin 10 (PEX10) Zellweger syndrome,
neonatal adrenoleukodystrophy
614870
614871
[322]
PEX12 Peroxin 12 (PEX12) Zellweger syndrome,
neonatal adrenoleukodystrophy, infantile Refsum disease
614859
266510
[323]
[324]
PEX13 Peroxin 13 (PEX13) Zellweger syndrome,
neonatal adrenoleukodystrophy
614883
614885
[325]
[326]
PEX14 Peroxin 14 (PEX14) Zellweger syndrome 614887 [327]
PEX16 Peroxin 16 (PEX16) Zellweger syndrome
Mild Zellweger syndrome spectrum disorder
614876
614877
[328]
[58]
PEX19 Peroxin 19 (PEX19) Zellweger syndrome 614886 [329]
PEX26 Peroxin 26 (PEX26) Zellweger syndrome,
neonatal adrenoleukodystrophy, infantile Refsum disease
614872
614873
[330]
PEX11β Peroxin 11β (PEX11β) Mild Zellweger syndrome spectrum disorder 614920 [331,332]
PEX7 Peroxin 7 (PEX7) Rhizomelic chondrodysplasia punctata type 1 215100
614879
[176–178]
[190]
Single peroxisomal enzyme and transporter deﬁciencies
Fatty acid β-oxidation
ACOX1 Acyl-CoA oxidase 1 (ACOX1) Acyl-CoA oxidase deﬁciency 264470 [333]
HSD17B4 D-Bifunctional proteina D-Bifunctional protein deﬁciency
Perrault syndrome 1
261515
233400
[334]
[85]
SCP2 Sterol carrier protein 2 (SCP2)b Sterol-carrier-protein X deﬁciency 613724 [102]
AMACR α-Methylacyl-CoA racemase α-Methylacyl-CoA racemase deﬁciency
Congenital bile acid synthesis defect 4
614307
214950
[93]
ABCD1 ATP-binding cassette transporter, subfamily D,
member 1 (ABCD1)
X-linked adrenoleukodystrophy 300100 [108]
ABCD3 ATP-binding cassette transporter, subfamily D,
member 3 (ABCD3)
ATP-binding cassette transporter, subfamily D, member 3 deﬁciency 616278 [335]
Fatty acid α-oxidation
PHYH/PAHX Phytanoyl-CoA hydroxylase (PHYH, PAHX) Refsum disease 266500 [170,336]
Ether phospholipid biosynthesis
GNPAT Dihydroxyacetone phosphate acyltransferase
(DHAPAT)
Rhizomelic chondrodysplasia punctata type 2 222765 [179]
AGPS Alkyl-dihydroxyacetone phosphate synthase
(ADHAPS)
Rhizomelic chondrodysplasia punctata type 3 600121 [180]
FAR1 Fatty acyl-CoA reductase 1 (FAR1) Rhizomelic chondrodysplasia punctata type 4/peroxisomal fatty acyl-CoA
reductase 1 deﬁciency
616154 [183]
PEX5 Peroxin 5 long isoform (PEX5L) Rhizomelic chondrodysplasia punctata type 5 – [185]
Bile acid maturation
BAAT Bile acid CoA:amino acid N-acyl-transferase (BAAT) Familiar hypercholanemia/bile acid-CoA: amino acid N-acyltransferase
deﬁciency
607748 [337]
Glyoxylate metabolism
AGXT Alanine-glyoxylate aminotransferase (AGXT, AGT) Primary hyperoxaluria type I 259900 [338]
Hydrogen peroxide metabolism
CAT Catalase Acatalasemia 614097 [339]
Others
ALDH3A2 Fatty aldehyde dehydrogenase (FALDH)c Sjögren–Larsson syndrome 270200 [340]
DAO D-Amino acid oxidase (DAO, DAAO) Amyotrophic lateral sclerosis 105400 [254]
a Alternative names: 17-β-hydroxysteroid dehydrogenase IV (HSD17B4)/multifunctional protein 2 (MFP2).
b Alternative name: sterol carrier protein X (SCPX).
c Two isoforms are known residing in peroxisomes and the ER, which precludes attribution of the disease to a particular variant.
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transporter deﬁciencies have a broad heterogeneity, related to dif-
ferences in the physiological role of the affected metabolic pathway
or reaction [5]. In this group of inherited diseases, mutations have
been identiﬁed in 13 different genes encoding peroxisomal enzymes
and in two genes encoding peroxisomal transporter proteins (Table 1;
Fig. 1).
The brain is the most elaborate organ of the mammalian body and
consists of a variety of tissue-speciﬁc cell types: neurons (withhundreds of different subtypes), oligodendrocytes, astrocytes and mi-
croglia. These differ in structure and function but cooperate tightly to
perform all the tasks attributed to the brain. Moreover, the structural
complexity of brain organization requires a precisely coordinated devel-
opmental process to accomplish its proper formation. The central ner-
vous system (CNS; brain and spinal cord) and the peripheral nervous
system (PNS) use the same mechanisms for communication between
neurons, which transmit information by chemical synapses between
cells. In addition, efﬁcient propagation of the electrical signal (action
Fig. 1. Schematic drawing linking peroxisomal disease-related proteins to individual metabolic pathways. Upper part: Proteins are grouped according to their function in biosynthetic or
degradativemetabolic pathways, ROShomeostasis, proteolytic activity, transport ofmetabolites across theperoxisomalmembrane (ABCDandPMPproteins), and the import ofmatrix and
membrane proteins (PEX proteins). Ovals represent proteins that are involved in peroxisomal functions (not complete); gray ovals, proteins for which mutations have been linked to a
human disease (for full name see Table 1). The degradation of various fatty acids and bile acid precursors is symbolized by the frame depicting the homodimeric transporters (ABCD1–
3) and the terms α- and β-oxidation, illustrated in more detail below. Lower part: Proteins are grouped into the degradation pathways for different activated fatty acids (fatty acyl-
CoA: saturated, unsaturated, dicarboxylic, branched-chain) and the side chain shortening of di- and trihydroxycholestanoic acid (DHCA/THCA) during bile acid biosynthesis (all via β-ox-
idation) and the oxidative removal of one carbonunit frombranched-chain fatty acids (α-oxidation). Several proteins are involved in the subsequentmodiﬁcation of theβ-oxidation prod-
ucts, either by thiolytic cleavage (thioesterases, ACOT), substitution of CoA for carnitine (carnitine transferases, CRAT and CROT) or amidation of the CoA-activated side chain of bile acids
(amino transferase, BAAT). FALDH*, two isoforms are known residing in peroxisomes and the ER, respectively, which precludes attribution of the linked disease, Sjögren–Larsson syn-
drome, to a particular variant. Synthetase, CoA-activation is essential for the link between α- and β-oxidation, but the exact enzyme has not yet been assigned. PEX, peroxin; cargo-PTS1
and PTS2-cargo, representative peroxisomal matrix proteins harboring a PTS1 or PTS2 motif, respectively;mPTS-cargo, representative peroxisomal membrane protein harboring a motif
for targeting of peroxisomalmembrane proteins (mPTS). 4,8-DMN-CoA, 4,8-dimethylnonanoyl-CoA. Proteins not included in Table 1: 2-HACL, 2-hydroxyacyl-CoA lyase; ABCD2, ATP-bind-
ing cassette transporter D2; ACAA1, acetyl-CoA acyltransferase 1; ACOT4, acyl-CoA thioesterase 4; ACOT8, acyl-CoA thioesterase 8; ACOX2, acyl-CoA oxidase 2; CRAT, carnitine O-acetyl-
transferase; CROT, carnitine O-octanoyltransferase; DDO, D-aspartate oxidase; DECR2, dienoyl-CoA reductase 2; ECH1, enoyl-CoA hydratase 1; EPHX2, epoxide hydroxylase 2; GSTK1,
glutathione S-transferase kappa-1, IDE, insulin-degrading enzyme; LONP2, lon peptidase 2; PAO, polyamine oxidase; PIPOX, pipecolic acid oxidase; PECI, peroxisomal D3,D2-enoyl-CoA
isomerase; PMP22, peroxisomalmembrane protein of 22 kDa; PMP34, peroxisomalmembrane protein of 34 kDa; PRDX1, peroxiredoxin 1; PRDX5, peroxiredoxin 5; SOD1, superoxide dis-
mutase 1; TYSND1, trypsin domain-containing 1
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of the axons. The complexity of the nervous system and the tight inter-
action of the involved cell types render this system susceptible to distur-
bances. Accordingly, metabolic dysfunction associated with a complete
loss of all peroxisomal functions or of individual enzymatic reactions
is often linked to perturbation of brain formation, function or mainte-
nance. Thus, pathological aberrations of the nervous system are
prominent features in most peroxisomal disorders; the most severe
form of PBD has traditionally been designated “cerebro-hepato-renal
syndrome” highlighting the apparent brain dysfunction in these pa-
tients. The brain pathology in peroxisomal disorders can be grouped
into three major classes: i) abnormalities in neuronal migration or dif-
ferentiation, ii) defects in the formation or maintenance of central
white matter, and iii) post-developmental neuronal degeneration [6].This review summarizes the current knowledge on the contribution
of the various peroxisomal pathways to proper brain functionwith par-
ticular consideration of the different cell types of the nervous system.2. Metabolic functions of peroxisomes
Peroxisomes harbor a variety of enzymes, which either serve to
catalyze a single chemical reaction or cooperate with other peroxisomal
enzymes in a series of coupled reactions constituting a complete
metabolic pathway. A selection of these enzymes, which exert impor-
tant peroxisomal functions in the context of the brain, is schematically
depicted in Fig. 1. For further details on these metabolic pathways, the
reader is referred to excellent previous reviews [3] [7].
937J. Berger et al. / Biochimica et Biophysica Acta 1863 (2016) 934–955A prominent example of such a metabolic pathway is the peroxi-
somal degradation of diverse fatty acids by β-oxidation (Fig. 1, lower
part). Here, many different substrates are handled, such as straight-
chain saturated VLCFA, unsaturated fatty acids, dicarboxylic acids and
a subset of branched-chain fatty acids, but also the side chain of inter-
mediates in bile acid biosynthesis (di- and trihydroxycholestanoic
acid; DHCA and THCA) [7]. The β-oxidation cycle is a four-step reaction,
executed by three enzymes: an acyl-CoA oxidase (ACOX1 or ACOX2), a
bifunctional protein (DBP or LBP) and a thiolase (ACAA1 or SCPx), in
which the paralogous/homologous enzymes show different extents of
substrate speciﬁcity. Each cycle results in a shortening of the acyl-CoA
backbone and the release of acetyl-CoA or propionyl-CoA (in case of
branched-chain fatty acids). Auxiliary enzymes help to circumvent
special properties of unsaturated or branched-chain fatty acids that
would be incompatible with continuous β-oxidation. The substrates of
β-oxidation are imported into peroxisomes in an activated form, as
CoA-ester, via ATP-binding cassette (ABC) transporter proteins
(ABCD1, ABCD2 and ABCD3) and the products are further processed ei-
ther into carnitine esters by carnitine ac(et)yl-transferases (CRAT and
CROT) or into free acids by thioesterases (ACOT4 and ACOT8) (Fig. 1,
lower part). A subtype of branched-chain acyl-CoA (especially phytanic
acid) ﬁrst has to be oxidatively decarboxylated via the α-oxidation
pathway [7]. This process involves hydroxylation of the carbon next to
the carboxylate ester (by PHYH) and a subsequent oxidative cleavage
to split off the carboxyl group by 2-hydroxyacyl-CoA lyase (2-HACL)
releasing an acyl-aldehyde. The subsequent steps involve an oxidation
of the aldehyde (fatty aldehyde dehydrogenase; FALDH) and an activa-
tion of the generated fatty acid by a still unknown acyl-CoA synthetase.
Furthermore, the early steps of ether phospholipid biosynthesis are
exerted by peroxisomal enzymes (Fig. 1, upper part), which reside
either inside (DHAPAT, ADHAPS) peroxisomes or at the outer side
(FAR1, AADHAPR) [3]. This metabolic pathway consists of a series of
reactions; the ﬁrst, carried out by dihydroxyacetone phosphate acyl-
transferase (DHAPAT) combines dihydroxyacetone phosphate (DHAP)
with a fatty acid, which is then exchanged for an long-chain alcohol
by alkyl-DHAP synthase (ADHAPS). This long-chain alcohol is generated
fromanother fatty acid by a fatty acyl-CoA reductase (FAR1) at the outer
side of peroxisomes. Finally, the carbonyl group of the original dihy-
droxyacetone phosphate is reduced by alkyl/acyl-dihydroxyacetone
phosphate reductase (AADHAPR) to enable further processing at the
endoplasmic reticulum (ER).
Other peroxisomal enzymes can exert their function more indepen-
dently (Fig. 1, upper part) such as the enzymes of the reactive oxygen
species (ROS) detoxiﬁcation system (peroxiredoxin 1/5, PRDX1/5; su-
peroxide dismutase 1, SOD1; epoxide hydrolase, EPXH2; glutathione-
S-transferase kappa 1, GSTK1 and catalase, CAT), which together
prevent the accumulation of reactive compounds, as reviewed in [8].
Also several enzymes acting on amino acids and their derivatives
(pipecolic acid oxidase, PIPOX; D-aspartate oxidase, DDO; D-amino
acid oxidase, DAO; alanine:glyoxylate aminotransferase, AGXT) or
other oxidative enzymes like polyamine oxidase (PAO) act in isolation
[3]. Furthermore, several proteins with a protease domain have been
found in peroxisomes (lon peptidase 2, LONP2; insulin-degrading
enzyme, IDE; trypsin domain-containing 1, TYSND1) and some mem-
brane proteins (peroxisomal membrane protein of 22 kDa, PMP22;
and peroxisomal membrane protein of 34 kDa, PMP34), which trans-
port a variety of smaller organic compounds such as nicotinamide-
adenine-dinucleotides (NAD), CoA, or ATP [9].
The enzymes known to be dysfunctional in patients suffering from
inherited peroxisomal disorders are distributed across these pathways
(Fig. 1, gray ovals). However, the relative physiological contribution of
each enzymemay differ drastically. Consequently, the pathological con-
sequences of their functional loss range from very severe diseases, like
D-bifunctional protein (DBP) deﬁciency (see chapter 5.2.2.), to diseases
that affect selective tissues but not the brain, like AGXT deﬁciency
causing primary hyperoxaluria type 1, which involves the kidneys [10].3. Brain peroxisomes and how they differ from peroxisomes in
other tissues
Although peroxisomes are present in all mammalian cell types,
except for red blood cells, they contribute to the function of the CNS in
speciﬁc ways. On the one hand, peroxisomes generate building blocks
(intermediates) for the biosynthesis of complex lipids such as ether
phospholipids, which are important components of myelin, the mem-
brane processes of oligodendrocytes that ensheath and isolate axons.
Moreover, peroxisomes exert the last step in the biosynthesis of the
very long-chain polyunsaturated fatty acid docosahexaenoic acid
(DHA; C22:6 n-3), which has important roles in the nervous system
[11]. This fatty acid is enriched in phospholipids including ether
phospholipids and, either directly or after enzymatic conversion to a
variety of bioactive derivatives, plays an important role in signaling
[12]. On the other hand, peroxisomes degrade toxic compounds that
can either interfere with proper brain formation or damage brain
structures (e.g., phytanic acid). Furthermore, peroxisomal enzymes de-
grade D-amino acids such as D-aspartate and D-serine, whichmodulate
synaptic signaling by altering the efﬁciency of synaptic transmission
(Fig. 3A, left panel).
In the brain, peroxisomes appear as electron-dense single
membrane-bound organelles that have been detected in all neural cell
types, namely in neurons [13], oligodendrocytes [14,15] and astrocytes
[13] and microglia and endothelial cells [16]. Brain peroxisomes in
general, and neuronal peroxisomes in particular, are smaller than per-
oxisomes from other tissues and, thus, were termed microperoxisomes
[17]. However, for the sake of simplicity, we use the term peroxisomes
for all structures within this review. In cultured cells from rat brain,
punctate peroxisomal immunoreactivity was found in mixed glial cells
and established oligodendrocyte cultures [18], as well as in astrocytes
and neurons [19].
The distribution of peroxisomes in the brain has been investigated
by different techniques such as cytochemical detection of enzymatic ac-
tivities restricted to peroxisomes including 3-aminotriazol-sensitive
precipitation of diamino-benzidine for catalase, conversion of D-
proline for detection of DAO or of D-aspartate for DDO [20]. Moreover,
immunohistochemistry, immunoﬂuorescence microscopy and electron
microscopy have been used. However, it is important to keep in mind
that many studies examined the presence and abundance of a single
peroxisomal protein, thus possibly detecting only a subset of
peroxisome-positive cells. Therefore, it is necessary to combine the dif-
ferent investigations to obtain an insight into the accurate distribution
and abundance of all peroxisomes in the brain. Comparison of DAO
and catalase activity revealed that in the locus coeruleus of the rat
brain, peroxisomes that stained positive for catalase activity were
found in various cell types, whereas DAO activity-positive peroxisomes
were restricted to astrocytes [13]. Similar results were obtained in the
cerebrum and in the PNS [13]. In the cerebellum, punctate catalase
immunoreactivity (characteristic of a peroxisomal localization) was
predominantly observed in Bergmann glia (astrocytes), whereas in
Purkinje cells, catalase appeared evenly distributed. This ﬁndingwas re-
capitulated in explanted cells from the cerebellum, inwhich catalase ap-
peared cytosolic (not enriched in peroxisomes) in calbindin-positive
Purkinje cells but punctate in astrocytes, whereas the peroxisomal
membrane protein PEX14 was found punctate in all cell types [21].
Moreover, the abundance of brain peroxisomes differs between brain
areas. Although single membrane-bound structures – detectable with
different methods to stain peroxisomes – can be found in most regions,
some brain areaswere reported to contain onlymodest numbers of per-
oxisomes [22]. However, peroxisome abundance also changes during
development. In the human brain, catalase-positive neurons emerged
early in evolutionary old structures such as the basal ganglia, the thala-
mus and the cerebellum (about 27–28 weeks of gestation), whereas in
the frontal cortex, they appeared later (around 35 weeks of gestation)
[15]. Similar observations were obtained when investigating the
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the deep white matter, catalase-positive glia appeared at 31–32 weeks
of gestation, their appearance shifting from the deep to the superﬁcial
whitematterwith increasing age [15]. Interestingly, during rat brain de-
velopment, peroxisomal activity (as represented by catalase activity)
remained constant in the cerebral cortex (a typical gray matter region),
whereas in thewhitematter, the activity changed over timewith a clear
peak accompanying the phase of myelination (during postnatal days
17–31) [24]. A similar increase in catalase activity was found in extracts
from murine cerebellum and brain stem [25], whereas a systematic
comparison by western blot analysis and catalase activity measure-
ments found the maximum level two days after birth and at later
timepoints, 15 and 49 days postnatally, the levels of peroxisomal
enzymes remained comparable [19].
This change in protein abundance is reﬂected at the mRNA level,
where the expression of genes coding for enzymes involved in the
samemetabolic pathways showed similar temporal proﬁles. In themu-
rine brain, the mRNA levels of the peroxisomal β-oxidation enzymes
(ACOX1, DBP, ACAA1a), the ABC transporters ABCD2 and ABCD3, and
the enzymes involved in ether phospholipid biosynthesis increased
after birth, reached a maximum during the ﬁrst weeks and then de-
clined. In contrast, the mRNAs for the enzymes involved in α-
oxidation were not detected during the ﬁrst postnatal weeks; and the
ABCD1mRNA was most highly expressed in the embryonic brain [26–
28]. This change in enzyme expression was conﬁrmed in a systematic
biochemical investigation of the abundance of peroxisomal enzymes
and their activity during mouse brain development. In this study, it
was found that peroxisomal activities decreased during postnatal devel-
opment (P2, P15, P49), irrespective of whether the activity was normal-
ized to the whole brain or to different brain regions (cerebellum,
hippocampus, cortex) [19]. This is in agreement with previous ﬁndings
in rat brain demonstrating that during the ﬁrst two postnatal weeks,
peroxisomes are more abundant than at later time points [22]. Howev-
er, this general trend contrasts with the reported amount of DAO activ-
ity in astrocytes of rat cerebellum, which was only observed in adult
rats, whereas no staining was observed in young animals (P3, P13,Fig. 2. Schematic representation of neuronalmigration defects in peroxisomal biogenesis disord
of cortical neurons are localized in discrete layers. In comparison, the cortical lamination is s
pachygyric (right panel) brains of caseswith Zellweger Syndrome is indicated (horizontal line).
Roman numerals to the left correspond to normal cortical layers.WM, white matter. (B) In the c
arranged into a single cell-thick layer at the border of the molecular (outermost) layer and the
calized to the granule cell layer and cerebellar white matter.P16) [13]. This might indicate a more speciﬁc contribution of DAO in
the adult brain, which could be linked to its function in the modulation
of neuronal synaptic transmission (see chapter 6.1.).
In the rat PNS, peroxisomes were described in Schwann cells, which
represent the myelinating cells of the PNS, as well as in dorsal root gan-
glion satellite cells and, less abundantly, in neuronal somata [29]. In
neurons of humandorsal root ganglia, peroxisomeswere readily detect-
ed based on immunohistochemistry for ABCD1 [30]. During early stages
of murine peripheral nerve (sciatic nerve) myelination, peroxisomes
appear to be diffusely distributed in the myelin sheath of Schwann
cells, whereas at later stages, peroxisomes were found to be enriched
in the myelin loops of the paranodal region [14]. These axon–glia con-
tact sites ﬂank the nodes of Ranvier, substructures of myelinated neu-
rons, in which highly abundant sodium channels in the axonal
membrane enable depolarization and reinitiation of the action potential
and thus permit the rapid saltatory propagation of the electrical signal
across long distances (Fig. 2A, left panel) [14].
4. Peroxisomes, brain and oxidative stress
Oxidative stress is a cellular state characterized by a high level of ROS
such as hydrogen peroxide (H2O2) or superoxide anions (O2.−), which
are considered to be mediators of the toxic effects associated with oxi-
dative stress. This state often arises as side effect of cellular disturbances
and has been amply described in connection with general peroxisomal
dysfunction, but also upon speciﬁc loss of an individual peroxisomal
function [31]. An increase in the concentration of ROS can originate
either from overproduction by one or more cellular producers
(individual enzymes or whole organelles), a reduction of the detoxify-
ing activity exerted by protective proteins (catalase, glutathione
peroxidase, superoxide dismutase, peroxiredoxin) or a shortage of
scavengingmolecules that normally buffer the emerging ROSmolecules
(e.g., glutathione, vitamin C and E) [32].
Peroxisomes are known to house a variety of oxidases generating
H2O2 and ROS, but they also enclose various ROS-detoxifying enzymes
such as catalase, GSTK1, PRDX5 and SOD1 to limit the detrimentalers. (A) In the cerebral cortex (neocortex) of a healthy individual (left panel), the cell bodies
everely disturbed and the border to the white matter in microgyric (middle panel) and
Similar abnormalities can also be found in cases of severe D-bifunctional protein deﬁciency.
erebellum of a healthy individual (left panel), the Purkinje cells (blue triangles) are strictly
thick granule cell layer. In Zellweger patients (right panel), many Purkinje cells are mislo-
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be overloaded. Artiﬁcial local production of ROS inside peroxisomes
can induce apoptosis, which can be rescued by ectopic overexpression
of peroxisomal detoxifying enzymes [33]. Exogenously added palmitate
can stimulate H2O2 production in peroxisomes of insulin-producing
cells [34] and exogenous application of VLCFA to a neuronal cell line
induces oxidative stress and mitochondrial damage [35]. Prolonged
hyperactivity of peroxisomes has also been linked to the overproduction
of H2O2 in the liver of acyl-CoA oxidase-deﬁcientmice [36]. Surprisingly,
in patients suffering from acatalasemia, an inherited peroxisomal
disorder caused by the loss of functional catalase, no neurological in-
volvement or brain abnormalities have been described, although this
enzyme plays such a prominent role in oxygen metabolism [37,38].
Moreover, peroxisomes are involved in the biosynthesis of
plasmalogens, which have been suggested as scavenger molecules for
H2O2 and ROS [39]. However, this effect is partially disputed, because
plasmalogen-deﬁcient mice do not show signs of increased oxidative
stress [40]. This issue has been extensively covered in previous reviews
[41,42]. Furthermore, the absence of one ormore peroxisomal functions
can indirectly increase the level of intracellular ROS, because under such
conditions, the accumulation of particular compounds such as VLCFAs
could be linked to disturbances in mitochondrial integrity, which
secondarily increases the production rate of ROS [43,44].
5. Brain dysfunctions in inherited peroxisomal disorders
5.1. Brain pathology under conditions of generalized peroxisome deﬁciency
in man and mice
This section focuses on the brain pathology in disorders of
peroxisome biogenesis or assembly, collectively known as peroxisome
biogenesis disorders (PBD). In these disorders, peroxisomes are not
formed normally, typically leading to deﬁciency of the entire spectrum
of peroxisomal functions. Thus, the observed pathology cannot be
attributed to individual peroxisomal metabolic pathways but rather
reﬂects the importance of the entire organelle for brain development
and maintenance. In addition, genetically engineered mouse models
with tissue- or cell type-speciﬁc inactivation of peroxisome biogenesis
demonstrate the importance of peroxisomes for the different brain
cell types, as well as the signiﬁcance of peroxisomal functions in
peripheral tissues for proper brain development.
5.1.1. Brain pathology in human patients with PBD
The PBD are divided into two types, i) Zellweger spectrum disorders
and ii) rhizomelic chondrodysplasia punctata (RCDP) type 1. In our
current understanding, the clinical syndromes constituting the
Zellweger spectrum (MIM#601539)2 are the Zellweger syndrome, neo-
natal adrenoleukodystrophy, and infantile Refsum disease, which de-
scribe a clinical spectrum of decreasing severity [45]. These were
originally described as independent disorders, long before the biochem-
ical and molecular bases of these disorders were understood [45]. In
1992, the ﬁrst gene defect associated with a PBD was identiﬁed [46].
By now, mutations in 13 different peroxin (PEX) genes (PEX1, PEX2,
PEX3, PEX5, PEX6, PEX10, PEX11b, PEX12, PEX13, PEX14, PEX16, PEX19,
PEX26) have been described in patients of the Zellweger spectrum
[45]. Patients with mutations in PEX7 are grouped into PBD because
more than one peroxisomal pathway is affected, although the peroxi-
somal structure remains intact. However, these patients have different
clinical symptoms than Zellweger spectrum patients and are clinically
not distinguishable from patients suffering from isolated disorders of
ether phospholipid synthesis; hence, the associated brain pathology
will be discussed in Section 5.5.2 When MIM numbers are indicated within this manuscript, we always refer to pheno-
type MIM numbers (online source: www.omim.org) characterizing the respective
disorder.The identiﬁcation of PBD complementation groups and their genetic
basis has revealed that there are no clear boundaries between Zellweger
syndrome, neonatal adrenoleukodystrophy and infantile Refsum dis-
ease, as they can all be caused bymutations in the same gene. However,
a genotype–phenotype correlation has been described for PEX genemu-
tations [45]. The nature and location of themutations determinewheth-
er themutated peroxin can still contribute to the import machinery and
allows residual metabolic functions of the peroxisomes in these
patients. In recent years, increasing numbers of patients have been
described with a later onset of the disease [47]. In accordance, also the
neurological manifestations vary from primarily neurodevelopmental
alterations in the most severe phenotypes to mainly degenerative
abnormalities in the milder cases [48].
In patients with Zellweger syndrome, themost prominent feature of
the brain pathology is a malformation of the cortex, which has been at-
tributed to neuronal migration defects. The abnormalities in the
cytoarchitecture of the cerebral cortex are usually bilateral and approx-
imately symmetrical [49,50]. In these patients, often a local thickening
of small convolutions (gyri) on the surface of the brain occurs around
the central sulcus (centrosylvian pachygyria), causing a reduced depth
of the ﬁssions/involutions. Moreover, in these areas, an excess of local
convolutions on the surface of the brain is observed (polymicrogyria).
The cytoarchitectonic pattern of the cerebral cortex is disturbed in the
microgyric and pachygyric areas (Fig. 2A). These abnormalities were
characterized in terms of the relative positions of speciﬁc neuronal sub-
sets and the patterns of neuronal arrangements into radial groups
(Fig. 2A) [50]. In the polymicrogyric cortex, typically a fusion of themo-
lecular layers is associated with a modiﬁed distribution of medium to
large pyramidal cells originating from the deep cortex. This causes a de-
crease in the numbers of neurons in the outer layers (layer II and layer
III) of the cortex; instead, these neurons are located in the deep cortex
and within heterotopias of subcortical white matter (Fig. 2A) [6]. Less
severe cerebral migratory abnormalities were reported in neonatal ad-
renoleukodystrophy [51]. To date, no migration defects have been de-
scribed in infantile Refsum disease, the least severe form of the
Zellweger spectrum. Another striking morphological aberration linked
to neuronal migration defects is the heterotopic localization of Purkinje
cells in the cerebellar white matter (Fig. 2B) [6,49,50].
In addition to these migration defects, within their ﬁrst year of life,
all patients with Zellweger syndrome display white matter abnormali-
ties in the CNS, which have been observed by histological analyses
and brain magnetic resonance tomography (MRT) studies [52–55]. Be-
cause myelination is still ongoing during this early period, it cannot be
clearly established, whether the lack of peroxisomal functions causes
abnormal myelination, early demyelination or both processes simulta-
neously [56]. Neuropathological examination of brains obtained from
three cases of neonatal adrenoleukodystrophy revealed a severe degen-
eration of the white matter involving both hemispheres of cerebrum
and cerebellum,while the axonswere preserved [57]. In the cerebellum
of one case, overabundance of reactive astrocytes in the white matter
was associated with perivascular cuffs of mononuclear cells [57]. Het-
erotopic Purkinje cells were found to be aggregated in irregular clumps
in the subcortical areas of the cerebellar cortex in two of the three cases
[57]. In some cases, mild initial symptoms are later followed by severe
CNS demyelination and death of the patient [53,55,56]. In the mildest
forms of the Zellweger spectrum, patients can survive into adulthood
[47,58,59]. In a study of 19 patients (16–35 years old) with such a
mild Zellweger spectrum disorder, magnetic resonance imaging (MRI)
revealed white matter abnormalities in nine of the patients. These ab-
normalitieswere restricted to the cerebellar hilus of the dentate nucleus
and/or theperidentate region [47]. During infancy, four of these patients
suffered from hypotonia, ﬁve from failure to thrive, 12 had a visual
handicap due to retinal degeneration and eight presented with hearing
impairment. During childhood, all 19 patients had amoderate to severe
developmental delay as well as a reduction/loss of visual and hearing
abilities and seven did not achieve structured speech. The predominant
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by different combinations of cerebellar syndrome, pyramidal tract dys-
function andperipheral neuropathy. Interestingly, at the timeof diagno-
sis, 17 of these patients had a blood metabolite proﬁle typical of a
peroxisomal disorder; but at later time points the concentration of
many originally accumulating metabolites had declined and, in some
patients, even a complete normalization was observed. In particular,
the levels of intermediates of bile acid biosynthesis (DHCA, THCA) and
of pipecolic acid declined during the observed time period in many pa-
tients, whereas VLCFA and plasmalogen levels normalized only in some.
This implies that, based on plasma metabolites linked to peroxisomal
function, some of these patients would have escaped the diagnosis of
a Zellweger spectrum disorder. Other studies reported normal VLCFA
levels in plasma of late-onset patients with a PEX2mutation [59] or nor-
mal plasmalogen levels in plasma of patients with PEX16 mutations
[58]. Accordingly, for the Zellweger spectrum, separate MIM numbers
have been assigned according to the severity of phenotypes (Table 1).
These ﬁndings indicate that the level of peroxisome-relatedmetabolites
in plasma may not necessarily reﬂect the level of accumulation in tis-
sues. This is of great relevance for the interpretation of alterations of
plasmalogen levels in plasma of patients withmore common neurolog-
ical diseases (see Section 6.4.).
5.1.2. Brain pathology inmousemodels of the Zellweger spectrum disorders
Currently, several mouse models of the Zellweger spectrum
disorders are available, which are represented by mice with targeted
deletions in the genes encoding the peroxins PEX2, PEX5 or PEX13
[60–62]. Recently also a knock-in mouse model carrying a missense
mutation in the Pex1 gene (Pex1-G844D) was reported, which recapitu-
lates the most frequent mutation in the human Zellweger spectrum
disorders with a milder pathology [63]. As Pex7-deﬁcient mice repre-
sent a model for RCDP type 1, but not for Zellweger spectrum disorders,
we discuss this model in the context of ether phospholipid deﬁciency
(Section 5.5.). Moreover, mouse models with Pex11α [64] and Pex11β
[65] deﬁciencies have been generated.
The phenotype of mice with Pex2, Pex5 and Pex13 deﬁciency resem-
bles the severe form of human Zellweger syndrome. These mice are
born alive, but are growth-retarded and severely hypotonic. Moreover,
they do not feed and die within 6–24 h after birth [60–62]. When the
Pex2mutation was maintained on a mixed genetic background (Swiss
Webster×129Svev), about 25% of the Pex2−/− pups survived for one
to two weeks [66]. Furthermore, postnatal survival could be improved
by oral bile acid application (9% alive after 30 days) [67]. In all mice
with a global peroxisome deﬁciency (Pex2, Pex5 and Pex13 deﬁciency),
a reduced thickness of the neocortical plate was observed, which re-
ﬂects abnormal lamination that has been linked to impaired neuronal
migration and increased cellular density in the underlyingwhitematter
[60–62]. Also cerebellar malformation was explored in all three models
of PBD revealing abnormalities in cerebellar foliation. However, because
the cerebellum develops largely postnatally in mice, a detailed charac-
terization of cerebellar development was only possible in the longer
surviving (Swiss Webster×129Svev) Pex2−/− mice [68,69]. These
studies revealed multiple anomalies affecting the interaction of
climbing ﬁbers, granule cells and Purkinje cells and, thus, the cerebellar
circuitry. The number of granule cells was reduced due to defects in
their migration from the external to the internal granule cell layer and
increased apoptotic cell death. The Purkinje cells displayed stunted
dendrite trees with abnormal branches and spine morphology. The
disturbed dendritic spine compartmentalization reﬂected a delayed ar-
borization and translocation of the climbing ﬁbers from the inferior
olivary nucleus (the major excitatory input to the Purkinje cells from
the caudal medulla). In addition, progressive axonal swellings along
Purkinje cell axons indicated ongoing dystrophic, neurodegenerative
processes.
With regard to the Pex11-related mouse models, it should be noted
that in contrast to the other peroxins, the PEX11 family members actas membrane elongation factors during peroxisome proliferation [70].
Whereas PEX11α appears not to be essential for the formation of func-
tional peroxisomes, the absence of PEX11β leads to several pathological
features shared by the mousemodels of Zellweger syndrome, including
neuronalmigration defects, enhanced neuronal apoptosis, developmen-
tal delay, hypotonia and neonatal lethality [65]. As the import of perox-
isomal proteins is not impaired in thismousemodel, no accumulation of
VLCFA and only a slight decrease in plasmalogen levelswere detected in
the brain [65]. The mechanism, by which Pex11β deﬁciency causes
Zellweger-like symptoms, in spite of the mild metabolic defects,
remains to be resolved.
5.1.3. The importance of peroxisomal functions for individual cell types of
the brain
The power of mouse genetics provides an opportunity to discrimi-
nate the contribution of peroxisomal functions from different cell
types to brain development and function. The conditional inactivation
of selected genes in speciﬁc cell types or tissues has been used to gener-
atemicewith a deﬁciency in all peroxisomal functions restricted to sub-
sets of brain cells. By crossing mice with a “ﬂoxed” Pex5 gene (Pex5
ﬂanked by loxP recombination sites), which are susceptible to the re-
moval of the DNA region between the loxP sites by the cyclization
recombinase (Cre), and mice expressing Cre in a subset of cells, mouse
lines have been generated, in which peroxisomes are selectively absent
from different compartments of the CNS according to the speciﬁcity of
the Cre-driving promoters. When using mice, which express Cre under
the nestin promoter (Nestin-Cre drivermice), inactivation of Pex5 occurs
in all neural precursor cells at embryonic stages, but not in themicroglia
lineage. This results in the ablation of peroxisomal functions in the vast
majority of neurons, astrocytes and oligodendrocytes of mice already at
prenatal stages [71]. These Nestin-Pex5−/−mice appear normal at birth,
but develop substantial growth retardation after the ﬁrst postnatal
week. Progressive motor impairments ensue, resulting in lethargy and
death before six months of age. In these mice, peroxisome-dependent
metabolite levels were deranged (increased VLCFA, decreased
plasmalogen levels) in the brain at late embryonic stages, but were nor-
mal in the liver. In the developing brain, a defect in neuronal layer for-
mation in the cerebral cortex was observed indicative of neuronal
migration defects and, postnatally, delayed cerebellar development in-
cluding immature foliation and dendritic arborization of Purkinje cells
[72]. Marked hypomyelination was detected already during the second
to third postnatal week (probably due to insufﬁcient formation of mye-
lin) andwas found in all brain regions (later probably also due to demy-
elination), together with axonal loss, reactive astrocytes as well as
activated microglia and macrophages [73]. Also brain-speciﬁc (Nestin-
Cre-dependent) inactivation of Pex13 in mice resulted in a similar phe-
notype with impaired cerebellar development, neuronal cell death,
astrogliosis and microgliosis as well as signs of mitochondria-
mediated oxidative stress [74]. Similarly, selective knockout (KO) of
Pex5 in oligodendrocytes by using Cnp-Cre drivers had severe conse-
quences for the adult brain [75]. Interestingly, no developmental defects
were observed at birth or after two months although CNPase is
expressed in progenitors before myelination as well as in adult oligo-
dendrocytes. However, young adult mice gradually developed impaired
motor function and premature death due to axonal degeneration, pro-
gressive subcortical demyelination and neuroinﬂammation, starting at
two to six months of age. In contrast, peroxisome ablation in projection
neurons of neocortex and hippocampus, obtained with Nex-Cre driver
mice [76], or in astrocytes obtained with GFAP-Cre drivers [76], had no
obvious deleterious effect on brain development or function. This was
surprising, because Pex5 deletion in astrocytes resulted in accumulation
of VLCFA as well as reduced plasmalogen levels in the brain. Taken to-
gether, these studies indicate that in the murine brain, peroxisomes
are most crucial for oligodendrocytes and the myelin compartment.
However, also the selective loss of peroxisomal functions in hepato-
cytes of the liver, obtained by α-fetoprotein-Cre driver mice [72], results
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and cerebellar development (hypotrophy, increased apoptosis,
immature foliation, delayed granule cell migration and stunted Purkinje
cells). This ﬁnding is further corroborated by observations in Pex5-
deﬁcient mice (ubiquitous KO), in which liver-speciﬁc ectopic expres-
sion of Pex5 [77] resulted in partial rescue of the brain defects. These
studies indicate a role of brain-extrinsic effects (effects originating
from outside the brain) in CNS development in peroxisomal disorders.
The mechanisms are not resolved but Faust and collaborators showed
that bile acid treatment can partially restore the cerebellar anomalies
in Pex2-deﬁcient mice [69]. This treatment partially compensates for
the lack ofmature C24 bile acids in thismousemodel and, thus, restores
intestinal absorption of dietary lipids. However, it is unclear, whether
the beneﬁcial effect of this treatment on postnatal CNS/cerebellum
development is due to an improvedmetabolic state of the pups because
of increased lipid absorption, or prevention of steatorrhoea and
cholestasis, or whether the addition of mature bile acids reduces the
synthesis of bile acid precursors, whichmight impair CNS development.
However, the absence of developmental problems in the CNS of
racemase-deﬁcient mice, in which bile acid precursors accumulate as
well [78], renders an exclusive effect of bile acid precursors quite
unlikely.
5.2. Brain pathology in peroxisomal β-oxidation disorders in humans and
mice
As peroxisomes fulﬁll a variety of metabolic functions, which are
concomitantly ablated upon inactivation of peroxisome biogenesis (in
human patients suffering from Zellweger syndrome or in Pex-deﬁcient
mice), the attribution of particular aspects of brain pathology cannot
be traced back to a single pathway such as β-oxidation. The investiga-
tion of single enzyme and transporter deﬁciencies and mouse models
lacking individual peroxisomal enzymes or transporter proteins allows
a comparison of the physiological consequences of a selective loss of
individual metabolic pathways for brain function. However, even
these conditions have limitations, because metabolic pathways such as
the peroxisomal β-oxidation handle many different substrates, which
renders a direct correlation between the loss of an enzymatic activity
and a class of substrates impossible. Peroxisomal β-oxidation can
degrade VLCFA, branched-chain fatty acids, bile acid intermediates,
long-chain dicarboxylic acids and polyunsaturated fatty acids like
tetracosahexaenoic acid (C24:6), which undergoes one cycle of β-
oxidation in peroxisomes to produce DHA (C22:6). Moreover, fatty
acid-like compounds with signaling activity such as prostaglandins
and leukotrienes and some classes of xenobiotics are degraded in
peroxisomes [3]. Notably, some activities in the β-oxidation pathway
can be executed by more than one isoenzyme (Fig. 1). Human peroxi-
somes harbor two acyl-CoA oxidases, two bifunctional enzymes and
two thiolases, whereas murine peroxisomes are equipped with three
acyl-CoA oxidases, two bifunctional enzymes and three thiolases. As
most of the human isoenzymes of the peroxisomal β-oxidation have
different substrate speciﬁcities, some enzyme deﬁciencies lead to a
rather selective accumulation of speciﬁc peroxisomal β-oxidation
substrates, as will be discussed in the corresponding sections below.
5.2.1. Peroxisomal acyl-CoA oxidase deﬁciency
Patients with an inactivating mutation in ACOX1 lack peroxisomal
acyl-CoA oxidase activity, which is responsible for the degradation of
saturated VLCFA, polyunsaturated fatty acids and dicarboxylic acids,
but not branched-chain fatty acids or bile acid intermediates (Fig. 1).
Still, in many respects, the clinical presentation of acyl-CoA oxidase de-
ﬁciency (formerly pseudoneonatal adrenoleukodystrophy) resembles
Zellweger spectrum disorders, notably neonatal adrenoleukodystrophy
[79]. Most patients show neonatal onset of hypotonia, seizures, failure
to thrive, hepatomegaly, psychomotor retardation, sensory deafness,
absent reﬂexes, and visual loss with retinopathy and extinguishedelectroretinograms [80]. Patients may show some early delay in motor
development with a typical regression by 2–3 years of age. Brain
imaging (MRT and/or CT) revealed cerebral and/or cerebellar white
matter abnormalities in all investigated patients in a study involving
12 subjects, of whom three showed neocortical dysplasia [79]. As for
the Zellweger spectrum disorders, recently several cases of acyl-CoA
oxidase deﬁciency with less severe clinical phenotypes were reported,
which progressively developed neurological symptoms in later
childhood [81].
To recapitulate the human disease, a mousemodel with generalized
Acox1 deﬁciency was generated [82], in which VLCFA accumulate. In
Acox1−/− mice, marked peroxisome proliferation in the liver was ob-
served and accompanied by an increase in H2O2 concentration, leading
to the development of hepatic adenomas and carcinomas at 15 months
of age [36]. However, no brain pathology has been described for these
mice. To date, neither patients with mutations in ACOX2 nor Acox2 or
Acox3-deﬁcient mice have been described.
5.2.2. D-Bifunctional protein deﬁciency
In humans, two peroxisomal bifunctional proteins exist: D-
bifunctional protein (DBP; alternatively termedmultifunctional protein
2; encoded by HSD17B4) and L-bifunctional protein (LBP; alternatively
termed multifunctional protein 1; encoded by EHHADH), both having
a catalytic 2-enoyl-CoA hydratase activity and a (3R)-hydroxyacyl-CoA
dehydrogenase activity (Fig. 1). All known human patients with bifunc-
tional protein deﬁciency harbor mutations in the HSD17B4 gene [83],
whereas no patients with a mutation in the EHHADH gene, encoding
LBP, have yet been identiﬁed. The existence of two enzymatic domains
allows the classiﬁcation of mutations based on the location and the na-
ture of the mutation. Mutations affecting both domains or destabilizing
the protein are classiﬁed as DBP deﬁciency type I, those affecting only
the hydratase domain as DBP deﬁciency type II, and those solely affect-
ing the dehydrogenase unit as DBP deﬁciency type III. However, as both
enzymatic steps are essential for peroxisomalβ-oxidation, the complete
loss of both activities as well as of the individual enzymatic activities
causes neurodevelopmental abnormalities and death within the ﬁrst
two years of life [83]. The severe form of DBP deﬁciency mimics
Zellweger syndrome in all aspects including cranio-facial dysmorphism,
neuronal migration defects (similar to that depicted in Fig. 2A) and
premature death [84]. Also, demyelination of the central white matter
is present [83].
Similar to the Zellweger spectrum disorders, recently also patients
with unexpected phenotypes of DBP deﬁciency were identiﬁed using
next generation sequencing [85]. These patients presentedwith ovarian
dysgenesis, hearing loss, and ataxia comparable to Perrault Syndrome
(MIM #233400) demonstrating clinical overlap of DBP deﬁciency and
the genetically heterogeneous Perrault Syndrome [85]. One of the doc-
umented patients, who was 27 years old at the last examination [85],
had normal levels of VLCFA and phytanic acid [86]. Normal serum
VLCFA levels have been reported also in other patientswith later clinical
onset of DBP deﬁciency. The correct diagnosis in these cases was initiat-
ed by neuroimaging or whole exome sequencing [87,88]. This further
demonstrates that peroxisome-related neurological deﬁcits and the
level of metabolites linked to peroxisomal functions do not necessarily
correlate when measured in the blood of patients.
Amousemodel of DBP deﬁciency (here termedMfp2 deﬁciency) has
been described, in which VLCFA accumulate speciﬁcally in brain, and
the degradation of branched-chain fatty acids as well as thematuration
of bile acid precursors were disturbed [89].Mfp2-deﬁcient mice appear
quite normal at birth but are severely growth-retarded during the
lactation period. Their life span is markedly reduced with a part of the
population dying early (at around two weeks of age) [89] while the
rest lives for up to six months [90]. Notably, this is much longer than
the survival of Pex5-deﬁcient mice (6–24 h) [60]. Moreover, Mfp2-
deﬁcient mice do not show signs of neurodevelopmental abnormalities
such as migration defects at early time points [90] [91]; but later on,
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reﬂected by motor impairment and lethargy [92]. Thus, in contrast to
the human disorders, where Zellweger syndrome and DBP deﬁciency
are clinically very similar, their respective mouse models are remark-
ably different. Interestingly, the brain pathology of Mfp2-deﬁcient
mice resembles the conditional Nestin-Pex5 mouse model (see 5.1.3),
in which functional peroxisomes are absent from all neural cell types
of the CNS [71].
5.2.3. 2-Methylacyl-CoA racemase deﬁciency
The enzyme 2-methylacyl-CoA racemase (AMACR) inverts the steric
conﬁguration at the position next to the thioester, resulting in the con-
version of (2R)-methyl branched-chain fatty acids into (2S)-methyl
branched-chain fatty acids. Only branched-chain acyl-CoAs such as
pristanic acid or bile acid intermediates with the 2-methyl branch in
the S conﬁguration are substrates for peroxisomal β-oxidation. Accord-
ingly, pristanic acid and the bile acid intermediates DHCA and THCA, but
not VLCFA, accumulate in AMACR-deﬁcient patients (Fig. 1) [93]. The
phenotype of patients with AMACR deﬁciency (MIM#614307) often in-
volves adult-onset sensory neuropathy [94] and late-onset cerebellar
ataxia [95]. Occasionally, other symptoms and types of pathology have
been described such as white matter anomalies [96], relapsing enceph-
alopathy [97] and amore complex adult phenotype including peripher-
al neuropathy, epilepsy, bilateral thalamic lesions, cataract, pigmentary
retinopathy and tremor [98]. Finally, some patients had cholestatic liver
disease in the ﬁrst neonatal weeks [99].
The generation of a racemase-deﬁcient mouse model has been de-
scribed [78], but so far only the pathological features of peripheral
lipid metabolism have been investigated [100]. However, upon phytol
supplementation of the diet, the mice developed severe pathology in
the brain after 40 days, including demyelination and activation of
astroglial cells [101].
5.2.4. SCPx deﬁciency and gene redundancy of peroxisomal thiolase activity
and the consequences for brain function
In man, two enzymes with thiolase activity, acetyl-CoA acyltransfer-
ase 1 (ACAA1) and sterol carrier protein X (SCPx), are present in perox-
isomes (Fig. 1). However, only for SCPx, the thiolase required for the
breakdown of branched-chain fatty acids, a single patient with a
deﬁciency of the enzyme (MIM #613724) has been described so far
[102]. Among other clinical features, this adult patient presented with
dystonic head tremor and spasmodic torticollis; and cranial MRI
showed bilateral hyperintense signals in the thalamus, butterﬂy-like
lesions in the pons and lesions in the occipital region [102].
In themouse, three enzymeswith thiolase activity exist: two closely
related proteins (96% amino acid sequence identity) encoded by the dif-
ferentially regulated genes Acaa1a and Acaa1b, and SCPx. In a classical
gene KO model, Acaa1b deﬁciency showed a very mild phenotype and
hardly any accumulation of VLCFA, indicating a compensatory effect
from Acaa1a and/or Scpx in mice [103]. In Scpx-deﬁcient mice, methyl-
branched-chain fatty acid catabolism is impaired resulting in a mild
phenotype under standard conditions [104]. However, high phytol
diet treatment led to a much more severe phenotype, in which the
mice rapidly lost body weight and acquired an unhealthy appearance
and inactivity, reduced muscle tone, ataxia and trembling [104].
5.3. Brain pathology in X-linked adrenoleukodystrophy
Three peroxisomal ATP-binding cassette (ABC) transporters, ABCD1,
ABCD2 and ABCD3, mediate the translocation of activated fatty acids
and probably other compounds across the peroxisomal membrane, in
order to get metabolized within the peroxisomes (Fig. 1). The abun-
dance of these transporter proteins varies between cell types and tis-
sues [28,105–107]. Inherited defects in the ABCD1 (formerly ALD)
gene are the genetic basis for X-linked adrenoleukodystrophy (X-ALD;
MIM#300100) [108]. X-ALD is themost common peroxisomal disorderwith an estimated combined male and female incidence between
1:16,800 [109] and 1:30,000, with similar incidence rates across the
world [110]. Human ABCD1 transports CoA-activated saturated
straight-chain VLCFA across theperoxisomalmembrane for further deg-
radation by the peroxisomal β-oxidationmachinery (Fig. 1) [111]. Upon
ectopic overexpression in yeast, ABCD1 can mediate the transport of a
broader spectrum of substrates [112], and overlapping substrate speci-
ﬁcities have been demonstrated for the three peroxisomal ABC trans-
porters [113–115]. Because ABCD2 and ABCD3 as well as the
peroxisomal β-oxidation enzymes are intact in X-ALD, only saturated
straight-chain VLCFA accumulate, but to a variable extent in different
cell types and tissues. This selective substrate transport deﬁciency as
well as the overlapping functions of the peroxisomal ABCD transporters
explains why, in contrast to DBP deﬁciency and acyl-CoA oxidase
deﬁciency, some X-ALD patients can remain pre-symptomatic through
more than ﬁve decades, even in the complete absence of ABCD1 trans-
porter activity. In addition to the impaired degradation of VLCFA, prob-
ably also increased fatty acyl chain elongation of long- to very long-
chain acyl-CoA esters contributes to the accumulation of VLCFA (in
particular C26:0) in X-ALD. Leading studies of Stephan Kemp's group
suggest an important role of the rate-limiting enzyme in this process,
elongation of very long-chain fatty acids 1 (ELOVL1), in the homeostasis
of VLCFA in X-ALD [116,117]. Among the seven known ELOVL family
members, which have different chain length selectivity, ELOVL1 favors
saturated and monounsaturated CoA-activated fatty acids with a chain
length of 20 to 24 carbons [118,119]. Indeed, upon knockdown of
ELOVL1 mRNA in X-ALD ﬁbroblasts, the storage of C26:0 decreased
signiﬁcantly [116].
Although X-ALD does not involve any developmental defect or
delay, it is characterized by remarkable clinical heterogeneity. The
main phenotypes are adrenomyeloneuropathy (AMN) and cerebral
ALD (CALD), the devastating inﬂammatory and demyelinating form of
X-ALD [120]. Both phenotypes can occur within the same kindred
[121] and no general genotype–phenotype correlation exists for the se-
verity in X-ALD [122–125]. Adrenal insufﬁciency represents another
major pathological aspect in X-ALD, which often represents the initial
symptom and affects 80% of male patients before adulthood but is rare
in heterozygous female patients [126]. Virtually all male patients with
mutations in the ABCD1 gene eventually develop AMN, a slowly pro-
gressive myelopathy with typical onset in the third or fourth decade
of life. The earliest symptoms are usually urge incontinence and sensory
disturbances in the legs followed by spastic gait. The major neuropath-
ological feature in AMN is a distal dying-back axonopathy, which in-
volves the dorsal columns and corticospinal tracts in the lower
thoracic and lumbar regions [127], as well as the more proximal
segments of the corticospinal tracts in the internal capsule [128]. The
peripheral nerves are also involved, with primary axonal degeneration
in most AMN patients [129]. Evidence of myelopathy or peripheral
neuropathywas recently observed inmore than 80% ofwomen carrying
heterozygous ABCD1 mutations and older than 60 years. Thus, female
patients develop symptoms similar to those in male AMN patients but
at later age [130,131].
In the human brain, based on immunohistochemical detection,
ABCD1 is predominantly expressed in oligodendrocytes, microglia,
astrocytes and endothelial cells but not in most neurons, with the
exception of a few regions: hypothalamus, basal nucleus of Meynert,
periaqueductal gray matter and the locus coeruleus [16,30]. Further-
more, ABCD1 is also highly expressed in dorsal root ganglia, where the
neuronal cell bodies of the afferent sensory axons are located, which
degenerate in AMN [30]. Thus, pathophysiological involvement is
suggested for neurons as well as for oligodendrocytes in the case of
axonopathy. By electron microscopy, mitochondrial abnormalities
have been observed in neurons of AMN patients [132]. The mitochon-
drial abnormalities have been conﬁrmed and are believed to be a
major pathogenic factor contributing to neurodegeneration in AMN
(Fig 3A). Cytosolic deposits of crystalline lamellar lipids were observed
Fig. 3. Schematic representation of abnormalities of myelinated axons and synaptic transmission in peroxisomal deﬁciencies. (A) The left panel shows a myelinated axon at the level of a
node of Ranvier in a healthy control. The myelin sheath of oligodendrocytes (in the CNS) or Schwann cells (in the PNS) surrounds and isolates the axon, except at the node of Ranvier
allowing depolarization of the neuronal membrane and propagation of electrical signals. Note that a multitude of ion channels and Na+/K+-ATPases (not indicated) are located at the
node of Ranvier and entail a high energy demand. In the right panel, different pathological features are indicated that may contribute to the axonal degeneration frequently observed
in peroxisomal disorders, for example, adrenomyeloneuropathy (the late-onset variant of X-ALD). A scenario can be envisaged, where peroxisomal dysfunction and abnormal accumula-
tion of lipid metabolites in myelinating cells lead to unstable paranodal loops and a loss of axonal support resulting in energy deﬁcits and oxidative damage in the axons and progressive
axonal degeneration. (B) A normal synapse with the surrounding astrocytes is depicted (left panel), representative for a synapse of any neurotransmitter. D-Amino acid oxidase is indi-
cated for its role in D-serine degradation at e.g. glutamatergic synapses. The right panel shows several possible disturbances of synaptic function (red text) that could lead to altered neu-
rotransmission, as predominantly described in ether lipid deﬁciency. NT, neurotransmitter; DAO, D-amino acid oxidase
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cal cells, and Leydig cells of the testes. Cholesterol esters of VLCFA
constitute a major component of these crystalline structures. Further-
more, it has been reported that VLCFA can disturb calcium homeostasis
and causemitochondrial dysfunction in neuronal cell cultures aswell as
toxicity to oligodendrocytes [133].
About 60% of male X-ALD patients develop CALD, the fatal cerebral
demyelinating form of the disease. This can occur either in childhood,
most commonly between 5 and 10 years of age, before onset of AMN
(about 35%) or later in adolescence or adulthood, often on the
background of AMN (35%). In children, the ﬁrst symptoms are emotion-
al lability, hyperactive behavior, school difﬁculties, impaired auditory
discrimination and difﬁculties in vision [134]. These early clinical
symptoms are not speciﬁc and often the correct diagnosis of X-ALD is
delayed. This phase is followed by a rapidly progressing neurological
decline, typically leading to a vegetative state or death within two to
ﬁve years. For a male patient born with an ABCD1 mutation, it cannot
be predicted whether or when the cerebral form will develop. It iscurrently hypothesized that the cerebral inﬂammatory phenotype re-
sults from a “second hit”, superimposed on the axonal pathology
[120]. Based on the lack of a genotype–phenotype correlation in X-
ALD, it is likely that a combination of genetic, epigenetic and environ-
mental factors plays an essential role as trigger for the development of
CALD. This is also supported by the development of different clinical
phenotypes in monozygotic twins [135,136] and the observation that
moderate head trauma can initiate cerebral demyelination in AMN pa-
tients [137,138]. In magnetic resonance images of the brain of CALD pa-
tients, a typical enhancement of the border of the demyelinating lesion
is visible after gadolinium administration reﬂecting an increased per-
meability of the blood brain barrier due to amarked inﬂammatory reac-
tion [139]. In this active region, inﬁltration of macrophages, CD4+ and
CD8+cytotoxic T cells, aswell as activatedmicroglia and astrocytes can
be observed [140]. This severe neuroinﬂammation probably causes the
loss of oligodendrocytes, which die by cytolysis rather than by
apoptosis [140]. Expression of proinﬂammatory cytokines such as
tumor necrosis factor α, interleukin (IL)-1, IL-2, IL-6, IL-12 and
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microglia in the diseasemechanism is supported by the observation of a
zone within the perilesional white matter, immediately beyond the
actively demyelinating lesion edge, lacking microglia [144]. This might
be due to the migration toward the active age of the lesion. In the
same study, clusters of activated and apoptotic microglia were detected
within the subcortical white matter [144]. Another characteristic of the
inﬂammation in CALD is the resistance to anti-inﬂammatory therapy.
Based on our recent observations, we have suggested that this is due
to the intrinsic metabolic defect of macrophages and microglia in X-
ALD; these cells cannot degrade VLCFA, which they have taken up by
phagocytosing of myelin debris (particular rich in VLCFA in X-ALD),
and then fail to support normal immunological brain function [107,
123]. Based on this intrinsic defect, the continuous metabolic stress in
the macrophage/microglia populations could also be the reason why
only in rare cases a spontaneous arrest of brain inﬂammation occurs.
Allogenic hematopoietic stem cell transplantation [145,146] and
autologous stemcell-based gene therapy [147] can arrest the inﬂamma-
tory demyelinating processwith a typical delay of 12–18months, which
has been attributed to the slow replacement of microglia with bone
marrow-derived phagocytes [147,148]. It must be noted that, due to
the rapid disease progression, hematopoietic stem cell transplantation
is only beneﬁcial when performed at an early stage of disease.
Transcriptomic analyses of X-ALD brain tissue have indicated that
already in AMN patients, a proinﬂammatory status prevails [149].
Musolino and coworkers recently demonstrated that inactivation of
ABCD1 induces signiﬁcant alterations in the brain endothelium via c-
MYC and may thereby contribute to the increased trafﬁcking of
leukocytes across the blood–brain barrier [150]. As the cell-
autonomous (intrinsic) metabolic defect in the monocyte–macrophage
lineages is also present in AMN patients, together with blood–brain
barrier abnormalities, it appears reasonable that this fragile system is
predisposed for converting to the inﬂammatory form of X-ALD,
triggered by a broad spectrum of genetic and environmental factors.
In 1997, three independent groups had generatedmousemodels for
X-ALD by targeted inactivation of the Abcd1 gene [151–153]. Although
the biochemical phenotype of X-ALD (i.e., accumulation of saturated
VLCFA) was well replicated in all three models, Abcd1-deﬁcient mice
did not experience brain inﬂammation and demyelination as seen in
humans with CALD. However, after 18 months of age, these mice start
to develop a late-onset, mild motor behavior phenotype with resem-
blance to AMN including sciatic nerve conduction abnormalities and
mild signs of axonopathy and myelin instability in the spinal cord
[154]. Interestingly, Abcd1 deﬁciency could further enhance microglia
activation and axonal degeneration inmicewithmildmyelin abnormal-
ities caused by the loss of the myelin-associated glycoprotein [155]. It is
intriguing that also Abcd1/Abcd2 double-deﬁcient mice do not develop
brain inﬂammation or demyelination [156], in spite of the ﬁnding that
Abcd1/Abcd2 double-deﬁcient peritoneal macrophages are metabolical-
ly much more severely affected than those from single transporter-
deﬁcientmice [157]. Also in thesemice, the neuropathology is restricted
mainly to axonopathy in the spinal cord and, with the major
contribution from Abcd2 deﬁciency, the dorsal root ganglia resulting in
a sensory neuropathy [156]. However, in the double mutant mice
these abnormalities develop about six months earlier than upon sole
Abcd1 deﬁciency.
In addition to exploring the effects of therapeutics aimed at normaliz-
ing VLCFA levels in vivo, thesemousemodels have been applied to further
characterize the mitochondrial damage noticed in X-ALD. The mitochon-
drial disturbances are probably not simply secondary effects due toVLCFA
accumulation itself [158] but more complex, involving oxidative stress
and cell type- and tissue-speciﬁc mechanisms that are of particular im-
portance for axonal degeneration in the spinal cord [43,159]. Interesting-
ly, lipoxidative damagewas observed early (at threemonths of age) in the
spinal cord of Abcd1-deﬁcient mice, long before the onset of any
neuropathological or motoric abnormalities were detected [160].Evidence for the role of oxidative stress in plasma of X-ALD patients
comes from an increased level of thiobarbituric acid reactive species
(TBA-RS) reﬂecting induction of lipid peroxidation, aswell as a decrease
of plasma total antioxidant reactivity, indicating a deﬁcient capacity to
rapidly handle an increase of ROS [161]. Additional evidence comes
from the ﬁnding of decreased levels of total and reduced glutathione,
which were associated with high levels of oxidized glutathione, in lym-
phocytes of X-ALD (predominantly AMN) patients [162]. Also, de-
creased plasma thiols and a high level of carbonyls were found,
additionally supporting the idea of oxidative stress – at least in blood
cells – in X-ALD patients [162]. Encouraging results were obtained
from a study applying an antioxidant cocktail consisting of vitamin E,
N-acetylcystein and lipoic acid to aging Abcd1-deﬁcient mice; this
dietary treatment was sufﬁcient to prevent the onset of locomotor
disability and axonal damage [163]. In line with these ﬁndings, also
oral administration of pioglitazone, an agonist of peroxisome
proliferator-activated receptor γ (PPARγ) and inducer of mitochondrial
biogenesis and respiration, was able to prevent mitochondrial damage
and oxidative stress in Abcd1-deﬁcient mice and could rescue the
locomotor disability and axonal damage in the Abcd1/Abcd2 double-
deﬁcient mouse model [164].
It has previously been suggested thatmitochondrial dysfunction and
oxidative stress within the axons are, at least partially, secondary to
dysfunctions in the oligodendroglia/myelin compartment resulting in
compromised support of axonal integrity [14,165,166]. In this context,
it is noteworthy that mice with a sole defect in a myelin protein, such
as proteolipid protein or 2′,3′-cyclic nucleotide phosphodiesterase,
display axonal dysfunction without demyelination in the spinal cord
and brain [167,168]. Most interestingly, mice with oligodendroglia-
selective peroxisome deﬁciency (see also Section 5.1.3.) can also be
considered as a phenocopy model for the inﬂammatory form of X-
ALD, recapitulating widespread axonal degeneration, progressive
subcortical demyelination and a proinﬂammatory milieu with B and T
cell inﬁltration of brain lesions [75].
Our current hypothesis envisions the inability to degrade VLCFA
combinedwith the increased elongation of VLCFA, in particular in oligo-
dendrocytes and neurons, as the primary cause of the late-onset, slowly
progressing, chronic myeloneuropathy in AMN (Fig. 3A). In heterozy-
gous X-ALD females, a similar disorder develops, but with a later onset
and slower progression;most likely random X-inactivation of the intact
ABCD1 copy leads to chimerism with a variable extent of ABCD1-
deﬁcient cells.5.4. Brain pathology in α-oxidation deﬁciency in man and mice
With respect to the peroxisomal fatty acid catabolism, 2-methyl
branched-chain fatty acids can directly enter the peroxisomal β-
oxidation pathway, whereas 3-methyl branched-chain fatty acids can-
not. Instead, 3-methyl branched-chain fatty acids can either be degrad-
ed byω-oxidation (for review see [169]) or by peroxisomalα-oxidation
(see Fig. 1). Among the enzymes involved in the α-oxidation pathway,
only phytanoyl-CoA hydroxylase (PHYH) has been associated with a
human disorder. Mutations in the PHYH gene have been established as
the genetic cause for classical Refsum disease (MIM #266500) [170,
171]. The 3-methyl branched-chain fatty acid phytanic acid, solely
taken up fromdietary sources, accumulates in patientswith Refsumdis-
ease. Because the disease is caused by the cumulative load of phytanic
acid in tissues, the age of onset varies from early childhood to the fourth
decade of life [56]. Refsum disease is characterized by progressive reti-
nitis pigmentosa culminating in blindness, peripheral neuropathy and
cerebellar ataxia [172]. When phytanic acid levels in the plasma remain
low due to dietary restriction or repeated plasmapheresis the progres-
sion of the symptoms can be arrested [173,174]. Because phytanoyl-
CoA hydroxylase is imported into peroxisomes via its PTS2 motif in a
PEX7/PEX5L dependent manner, the α-oxidation pathway is also
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A mouse model for Refsum disease has been generated by targeted
disruption of the Phyh gene [175]. Because standard mouse chow is
very low in branched-chain fatty acids, Phyh-deﬁcientmice have an un-
remarkable phenotype. However, dietary supplementation with 0.25%
phytol (the precursor of phytanic acid) for three weeks or 0.1% phytol
for six weeks caused ataxia, reﬂecting Purkinje cell loss and astrogliosis
in the cerebellum, and peripheral neuropathy, as revealed by nerve
conduction velocity measurements [175].
5.5. Nervous system pathology in ether phospholipid deﬁciency in man and
mice
So far, the biological functions of ether phospholipids (also simply
termed ether lipids), especially in the CNS, have not been fully
unraveled. However, many clues have been derived from the pathology
of ether phospholipid-deﬁcient mice and men. In humans, the lack of
these lipids causes the lethal disease RCDP, an autosomal recessively
inherited disorder with an estimated incidence of about 1:100,000. On
a genetic basis, several different types are distinguished; RCDP type 1
(MIM #215100) is evoked by mutations in the gene encoding PEX7
[176–178], the cytosolic receptor for peroxisomal import of PTS2-
containing proteins, whereas RCDP type 2 (MIM #222765) and type 3
(MIM #600121) are caused by mutations in the genes of the ﬁrst two
enzymes for biosynthesis of ether phospholipids, dihydroxyacetone
phosphate acyltransferase (DHAPAT, DAPAT; encoded by the GNPAT
gene) and alkyl-dihydroxyacetone phosphate synthase (ADHAPS;
encoded by the AGPS gene), respectively [179,180]. Due to the fact
that not only ether lipid biosynthesis but also peroxisomal α-
oxidation is impaired in RCDP type 1, it is classiﬁed as a PBD rather
than a pure ether lipid biosynthesis defect (see also Section 5.1). How-
ever, as the different RCDP types are clinically indistinguishable and
the clinical manifestations of Refsum disease (see Section 5.4) are con-
siderably less severe than that of RCDP type 1, we will cover RCDP
type 1 in the present section, which focuses exclusively on ether phos-
pholipids. The contribution ofα-oxidation deﬁciency to the clinical phe-
notypemay, however, be more prominent in RCDP type 1 patients with
a milder disease course (see below) [181,182]. In addition, it can be
speculated that some PEX7mutations affect proteins with certain PTS2
variants more strongly than others, thereby shifting the impact of the
affected pathways on pathology. Recently, two additional subtypes of
RCDP were identiﬁed based on the strong reduction of plasmalogen
levels in the patients and the similarity of their symptoms with
“classical” RCDP. First, the disorder of three patients with a deﬁciency
in FAR1, the gene coding for fatty acyl-CoA reductase 1, which generates
the fatty alcohols necessary to form the ether bond of the 1-alkyl chain
in ether phospholipid biosynthesis [183], was categorized as RCDP type
4 [80]. Second, the disease in patients withmutations speciﬁcally affect-
ing the long isoform of PEX5, PEX5L, which is required for efﬁcient
transport of cargo-loaded PEX7 to peroxisomes [184], was designated
RCDP type 5 [185].
The pathology in all subtypes of RCDP has been more or less
exclusively assigned to the lack of plasmalogens, although also other
ether phospholipids, like alkylphospholipids (lacking the vinyl ether
bond characteristic for plasmalogens) or platelet-activating factor, are
depleted in all types of RCDP and, in case of RCDP type 1, elevated plas-
ma levels of phytanic acid have been detected [186]. Irrespective of the
affected gene, all RCDP patients share common symptoms. The most
typical are the eponymous shortening of the proximal long bones
(rhizomelia) and epiphyseal stippling (chondrodysplasia punctata) as
well as congenital cataracts, joint contractures and growth and develop-
mental retardation [187]. The severity of the disease varies remarkably,
depending strongly on the residual activity of the affected enzyme and,
thus, the level of plasmalogens [188–191]. The most severe form of the
disease leads to lethality within the ﬁrst years of life, often due torespiratory failure. In contrast, patientswith a less severe disease course
present with only some of the characteristic symptoms and can survive
into young adulthood [192–194]. In human ether phospholipid deﬁ-
ciency, multiple pathological features affect brain development and
function. Mental disability and delayed motor development are hall-
marks of RCDP. However, the extent towhich the brain is affected varies
remarkably between patients and many of the symptoms are restricted
to the severer forms of the disease. Frequent delay in brain development
is further reﬂected by the ﬁnding of microcephaly in many RCDP cases.
Also epileptic seizures are very common but non-speciﬁc; seizure type
and frequency vary considerably and even affected childrenwithmulti-
ple seizure types have been reported [191,192]. The age of onset of
seizure activity is reportedly higher in milder cases of RCDP [191].
MRI examination in childrenwith RCDP has revealed varying patho-
logic features, although some cases, usually with a milder phenotype,
with unremarkable MRI results are also found [195]. Consistently,
most reports describe enlargement of ventricles and the subarachnoid
space, abnormalities in white matter signal intensity and delayed
supratentorial white matter myelination with frequent involvement of
the parieto-occipital area [195–200]. In line with myelination defects
also in the PNS, peripheral neuropathy has been reported in a clinical
subset of RCDP patients [201]. The severe form of the disease is usually
accompanied by progressive cerebellar atrophy [195], which is caused
by a pronounced loss of Purkinje cells and, to a lesser extent, other cell
types in the cerebellum [202]. Thus, in addition to peroxisomal β-
oxidation, also ether lipid biosynthesis appears to be crucial for cerebel-
lar development and function. Originally, it was assumed that increased
levels of phytanic acid contribute to the pathogenesis in the cerebellum
[52,202]. However, this hypothesis is strongly weakened by the
presence of cerebellar atrophy in a case of RCDP type 3, in which ether
lipid deﬁciency is the only metabolic defect, and, conversely, by the
absence of cerebellar atrophy in a case with particularly high phytanic
acid levels [191]. Sporadically, also other brain malformations have
been observed, like temporal atrophy [197], agenesis of the corpus
callosum [203], polymicrogyria [200], and pachygyria [204,205]. Neuro-
nal migration defects never reach the extent of those observed in
Zellweger syndrome (see Fig. 2A), but several cases with dysplastic
olivary bodies have been reported [202,206]. These ﬁndings emphasize
the fact that multiple peroxisomal functions are required for proper
development of the brain. In addition to the brain pathology, patients
suffering from the severe form of RCDP often develop stenosis of the
spinal canal (cervical stenosis) [195,207]. From a metabolic point of
view, MR spectroscopy of the brain has shown increased levels of
myo-inositol, a marker for gliosis, in line with previous reports of gliosis
in autopsy cases of RCDP [52,208]. MR spectroscopy has also revealed
elevated levels of mobile lipids, most likely caused by accumulation of
long-chain acyl-CoAs, as well as a reduction of choline and the presence
of acetate [199,209].
More insight into the pathomechanisms of ether lipid deﬁciency has
been gained from the generation of ether lipid-deﬁcient mousemodels.
Currently, geneKOmousemodels exist for RCDP types 1–3 (Pex 7,Gnpat
and Agps KO mice, respectively) [210–212], of which the ﬁrst two
models have been extensively characterized. Recently, also a mouse
model with inducible inactivation of alkyl/acyl-dihydroxyacetone phos-
phate reductase (AADHAPR; also named peroxisomal reductase activat-
ing PPARγ, PexRAP), the enzyme catalyzing the third step in ether lipid
biosynthesis (following theDHAPAT andADHAPS reactions) and shown
to be located at the outer face of the peroxisomal membrane [213], was
generated [214]. Furthermore, hypomorphic mouse models with resid-
ual transcript levels of the Pex7 [215] or the Agps [216] gene and, conse-
quently, residual levels of ether lipids have been described, which
mimic the milder form of the human disease. Many of the phenotypic
brain abnormalities described in these ether lipid-deﬁcientmice resem-
ble the observations in humans, with the advantage of animal models
being the opportunity to elucidate the underlying molecular processes
in more detail. Several studies have reported hypomyelination in
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lipid-deﬁcient mice [217,218], but no progressive demyelination as
seen in several mouse models of Zellweger syndrome [73]. Also myelin
of the PNS is affected in ether lipid-deﬁcient mice. Deﬁciencies in
myelination as well as Schwann cell development and differentiation
are found [219] resulting in peripheral neuropathy, as judged by
reduced motor neuron conduction velocity [220]. Remarkably, hypo-
and dysmyelination in the CNS of ether lipid-deﬁcient animals is accom-
panied by slight loss of axons and mild astrogliosis in some brain areas,
whereas microgliosis, which has been reported in several RCDP cases,
and the induction of inﬂammatory cytokines appear to be less
pronounced [73]. However, neuroinﬂammation with marked microglia
activationwas observed upon combined deﬁciency of Pex7 and Abcd1 in
11-months-old mice of mixed background (Swiss Webster and C57BL/
6J:129S1) [220] suggesting that ether lipid deﬁciency has little effect
on immune cell activation under basal conditions but more drastic
consequences in the presence of an additional immunostimulatory
factor. This concept is also supported by the ﬁnding that plasmalogens
suppressmicroglia activation after systemic injection of lipopolysaccha-
rides (LPS) in mice [221,222]. Furthermore, in murine cell lines,
plasmalogens seem to counteract neuronal death elicited by serum
starvation [223,224] by utilizing a process, which has been reported to
involve protein kinase B (AKT) signaling [224].
Cerebellar pathology is a striking feature in human cases of ether
lipid deﬁciency and has received special attention in the study of the
corresponding mouse models. Concordantly, foliation defects with un-
derdevelopment of ﬁssures, particularly affecting foliae VI and VII,
have been reported in Gnpat KO mice at different postnatal stages
[218,225]. Also, a migration defect of granule cell precursors [218] and
increased numbers of apoptotic cells in the external granule layer
[225] were found. Furthermore, hypomyelination in cerebellum (and
also in cortical areas) of Gnpat KO mice was accompanied by changes
in the architecture of the nodes of Ranvier resulting in a delay in the
propagation of action potentials [218]. Microscopy studies revealed
structural abnormalities in the innervation of Purkinje cells by parallel
ﬁbers and climbing ﬁbers aswell as axonal swellingswith accumulation
of smooth ER-like structures in Purkinje cells [218]. A detailed review of
cerebellar pathology in the context of ether lipid deﬁciency and other
peroxisomal disorders has been published recently [226].
In theﬁrst description of the Pex7KOmouse, neuronalmigration de-
fects in the neocortex of mutant embryos were reported; however,
these were much less pronounced than the migration deﬁcits in mice
completely lacking peroxisomes (e.g. Pex5 KOmice) [210]. Remarkably,
although similar techniques were used, no such alterations could be de-
tected in the brains of Gnpat KO mice [225], pointing towards a role of
phytanic acid in the development of thesemigration defects or potential
differences in the background strains of the mice used in the different
studies. Da Silva and coworkers also speculated that a not yet identiﬁed
peroxisomal protein harboring a PTS2 (and therefore being dependent
on PEX7) may be responsible for these apparently conﬂicting results
[227]. Bymaking use of the progress in the elucidation of PTS2 structure
requirements [228], future studies may substantiate this idea.
Involvement of the visual system is another typical feature of RCDP
that has been extensively studied in mouse models. Lens anomalies,
particularly bilateral cataracts, have been reported in all ether lipid-
deﬁcientmousemodels, including the hypomorphicmice. Furthermore,
hypoplasia of the optic nerve,microphtalmia, a persistent hyaloid artery
[211] and abnormal vascularization [229] were detected in Gnpat KO
mice. These ocular abnomalities have been covered in detail in previous
reviews [217,230].
So far, the molecular bases of mental disability in RCDP and the
nervous system pathology upon ether lipid deﬁciency in mice and
men have only been partially unraveled. Recently, a defect in the activa-
tion and downstream signaling of AKT was proposed to be responsible
for the myelination deﬁcit in the PNS of ether lipid-deﬁcient animals
[219]. It remains to be determined,whether a similar disturbance affectsthe CNS as well. Plasmalogen-deﬁcient myelin might be more prone to
oxidative damage [231]; however, this idea isweakened by theobserva-
tions of reduced rather than elevated levels of malondialdehyde and no
substantial change in other oxidative stress markers in the brains of
ether lipid-deﬁcient mice [40,73]. Studies in synaptosomes isolated
from cortex, mimicking the process of synaptic transmission, have re-
vealed a decrease in calcium-dependent release of the neurotransmit-
ters glutamate and acetylcholine in Gnpat KO mice [40]. This goes
alongwith decreased ATP content and an inability of synaptosomal res-
piration to adapt to the higher energy requirements of depolarization,
thereby offering a potential explanation for the defects in synaptosomal
neurotransmitter release [40] (Fig. 3B). Alternatively, changes in
membrane properties caused by plasmalogen deﬁciency might play a
role (Fig. 3B). The lack of ethanolamine plasmalogens (by far the most
abundant plasmalogen in the brain) is strictly compensated by the
structurally similar phospholipid phosphatidylethanolamine [40,232].
However, the characteristic biophysical properties conferred by
plasmalogens [233–235] could be essential for neurotransmission,
which involves repeated membrane fusion and constriction processes
(Fig. 3B). Furthermore, it has been suggested that deﬁciency in
plasmalogens impairs membrane rafts (formerly termed lipid rafts)
[211], small membrane domains that organize various cellular process-
es [236,237] and are enriched in plasmalogens [238]. However, the
impact of ether lipid deﬁciency on neurotransmission in vivo and the
underlying molecular mechanism still have to be elucidated in greater
detail.
No characterization of the nervous system in hypomorphic mouse
models of RCDP has been published so far, which could be due to the
milder phenotype of these mice, leaving the nervous system largely
unaffected.
6. The contribution of peroxisomes to more common
neurological disorders
Besides the fact that inherited peroxisomal disorders have drastic
consequences for the nervous system, a dysfunction of peroxisomes or
a dysregulation of peroxisomal metabolites has also been described in
a variety of other, more common, neurological diseases.
6.1. Involvement of D-amino acid oxidase in amyotrophic lateral sclerosis
and schizophrenia
Across evolution, D-amino acid oxidase (D-AAO, DAO) serves as a
tool to access the nutritional supply; however, in the brain, this enzyme
and its more speciﬁc counterpart D-aspartate oxidase (DDO) exert a
regulatory function in modulating the amount of the neuroactive D-
amino acids D-serine and D-aspartate, respectively [239]. DAO is perox-
isomal [13,240], contains a functional PTS1 motif [241] and interacts
with PEX5 [242] and also human DDO was shown to be located in
peroxisomes [243,244]. These enzymes are ﬂavin adenine dinucleotide
(FAD)-containing ﬂavoenzymes that oxidize certain amino acids,
thereby generating H2O2 as side product. DAO activity is abundant in
various human brain areas, but in the murine brain, some of the
corresponding regions contain markedly lower activity [245].
D-Serine binds to a speciﬁc extracellular site on the N-methyl-D-
aspartate (NMDA) receptor, which responds to glutamate as neuro-
transmitter, and further increases the signaling strength [246]. In the
brain, D-serine is generated in astrocytes and released into the synaptic
cleft [247], but also taken up from the synaptic cleft and degraded in as-
trocytic peroxisomes (see Fig. 3B).
Genetic linkage between the DAO locus and schizophrenia was ﬁrst
described by Chumakov and collaborators [248] and has since been ob-
served by several groups. In a later study, also elevated activity of DAO
was linked to schizophrenia [249], corresponding to reduced D-serine
levels and NMDA receptor hypoactivity. An increased activity of DAO
has been found in the cortex of patients [250] and the protein level
947J. Berger et al. / Biochimica et Biophysica Acta 1863 (2016) 934–955was increased in cerebellum and cortex [251], while reduced levels of
D-serine were observed in the cerebrospinal ﬂuid of patients [252].
Thus, inhibitors of DAO have been suggested as a therapeutic option
for schizophrenia [253]. However, it is unclear, whether the relevant
DAO activity is entirely peroxisomal in the astrocytes of patients.
Furthermore, a mutation in DAO was recently linked to a familiar
form of amyotrophic lateral sclerosis (ALS) [254], which is a fatal
human disease with neurodegenerative aspects affecting predominant-
ly motor neurons. The link to D-amino acid metabolism was supported
by the ﬁnding that in a mouse model for the familial form of ALS
(SOD1G93A), DAO activity in the spinal cord was reduced and,
consequently, D-serine levels were increased [255].
6.2. The link between ether lipid biosynthesis and autism
In 2013, a study applying whole exome sequencing identiﬁed a link
between mutations in PEX7 (RCDP type 1) and autism spectrum disor-
der, a range of neurodevelopmental conditions characterized by deﬁcits
in communication and social interaction and repetitive behavior, in a
familywith three affected children [256]. This observation supports pre-
viouswork showing an association between single nucleotide polymor-
phisms in the PEX7 gene and autism [257]. Prompted by their ﬁndings,
the authors reviewed previously reported RCDP cases for potential
signs of autism and found two further patients, which had later been di-
agnosed with neurodevelopmental conditions (one with autism, the
other with attention deﬁcit hyperactivity disorder) [256]. Additional
consolidation of the proposed link between plasmalogen deﬁciency
and autism comes from the ﬁnding of reduced levels of plasmalogens
in plasma and red blood cells of autistic patients [258,259]. The mecha-
nism, by which these two phenomena are connected, is still fully unex-
plored. Autistic features have, so far, not been regarded as a typical
symptom of RCDP (or other peroxisomal disorders), although one sim-
ilar case was already mentioned in 1999 [260]. The reasons for this
might be that many children affected by the disease do not reach a
stage, in which symptoms of autism manifest, and that treatment of
patients with RCDP focuses on other, more vital aspects. However, in
the future, clinicians may pay more attention to signs of autism in
RCDP patients, especially those suffering from the milder form of the
disease, which should help to substantiate a relationship between
deﬁciency in plasmalogens and autism.
6.3. Peroxisomes and Alzheimer's disease
Several links have been found between peroxisomes and
Alzheimer's disease (AD), themost common form of dementia affecting
several millions of people worldwide. Most prominently, a role of
plasmalogen deﬁciency in the etiology of AD is considered. Many
studies have conﬁrmed a severe depletion of ethanolamine
plasmalogens (ethanolamine is by far the most abundant plasmalogen
head group in the CNS), in post mortem brain tissue of AD patients
[261–266]; but also contradictory results exist [267]. The decrease in
brain plasmalogens emerges early in the disease course [262,268] and,
at least in gray matter, corresponds well with the deterioration of
cognitive function [262]. Although, to a lesser extent, also associated
with normal aging [269], depletion of brain plasmalogens appears to
be rather speciﬁc for AD and not a general feature of neurodegeneration.
Similar abnormalities could not be found in several other neurodegen-
erative diseases like Parkinson's disease or Huntington's disease [270].
Remarkably, deﬁciency of ethanolamine plasmalogens was also
repeatedly detected in peripheral blood of AD patients [271] rendering
these lipids potential as biomarkers for early and easy detection of the
disease [272].
The origin of plasmalogen deﬁciency in AD is currently still un-
known. Grimm and coworkers suggested that a dysregulation of AGPS
expression by the amyloid precursor protein intracellular domain and
oxidative damage by amyloid-beta (Aβ) peptides lead to instabilityand loss of activity at the protein (ADHAPS) level causing decreased
plasmalogen biosynthesis in AD [266]. Others speculate that an Aβ-
mediated increase in the activity of plasmalogen-selective phospholi-
pase A2 (PLA2), as detected in certain brain regions of AD patients
[273], depletes plasmalogens, thereby leading to excessive vesicular fu-
sion and, ﬁnally, synaptic failure [274]. Other alternative explanations
include increased oxidation of plasmalogens, in linewith their proposed
role as radical scavengers or excessive membrane degradation. Howev-
er, also impaired generalized function of peroxisomes could contribute
to the disturbance of plasmalogen homeostasis. This hypothesis is sup-
ported by ﬁndings of altered levels also of other peroxisomal metabo-
lites in the context of AD. For example, increased VLCFA levels were
detected in cortical tissues [263,264] and in peripheral blood [275] of
AD patients (although the latter results still require conﬁrmation).
Also, a decrease inDHA,whose endogenous de novo production requires
peroxisomes, in brain and liver [276] and a regional decrease in catalase
activity in the temporal lobe [277] were reported. Furthermore, our
group has previously identiﬁed an accumulation of peroxisomes in the
somata of neurons in the gyrus frontalis of AD patients accompanied
by a lack of peroxisomes in dendrites with abnormally phosphorylated
Tau protein, which might prevent the transport of peroxisomes into
these processes [263]. These results are complemented by studies in
mousemodels of AD, which imply that the number and protein content
of peroxisomes are stronglymodulated by the disease course [278,279],
and that these alterations are possibly triggered by excessive oxidative
stress and/or mitochondrial dysfunction.
As the etiology of AD is still unresolved, also the role of peroxisomal
dysfunction in the disease process is debated. It might be speculated,
though, that a decrease in peroxisomal activity, even if not the primary
cause of the observed pathology, aggravates oxidative stress and neuro-
degeneration in the AD brain. This ﬁts the observation that treatment
with a PPARα agonist, presumably by increasing the number of peroxi-
somes, protects cultured rat hippocampal neurons from Aβ-mediated
cell death [280]. In line with this, based on the changes in expression
of peroxisomal enzymes in rat cortical neuron cultures upon different
treatment regimens with Aβ, it has also been hypothesized that perox-
isomes represent an important defense mechanism against oxidative
stress triggered by Aβ [281]. In addition, elevated levels of VLCFA and
reduced levels of plasmalogens, both markers of peroxisomal dysfunc-
tion, have been suggested to stimulate the production of Aβ peptides
[282,283]. Detailed reviews covering the potential roles of plasmalogen
depletion [284] or peroxisomal impairment [285] in the context of AD
have been published in recent years.
An independent connection between peroxisomes andAD is provid-
ed by insulin-degrading enzyme (IDE; see Fig. 1), a Zn2+-dependent en-
dopeptidase, whose name-giving enzymatic activity was described
already in 1949 [286]. This peptidase can degrade a variety of physiolog-
ically relevant peptides reaching from glucagon via Aβ to insulin-like
growth factors (for review see [287]). IDE has been found in peroxi-
somes of cultured cells upon overexpression; and in rat liver, a fraction
of the protein was localized to peroxisomes [288–291]. Moreover, this
peptidase can degrade N-terminal peptides derived from PTS2-
carrying pre-proteins upon processing inside peroxisomes [288].
However, IDE was also described at many other subcellular locations
such as mitochondria [292], the nucleus [293], the plasma membrane
[294] or the extracellular space [295].
Because IDE can also degrade Aβ [295], this protease has been sug-
gested as a candidate for a modulatory function in the pathophysiology
of AD [296]. In linewith an important contribution of Aβ degradation by
IDE to the pathology of AD, an early genetic investigation described a
genetic link between late-onset AD and a region of chromosome 10
that includes the IDE locus [297]. However, some subsequent studies
using various single nucleotide polymorphisms found evidence for a
linkage while others did not. Moreover, a recent meta-analysis could
not conﬁrm indications for a contribution of individual single nucleotide
polymorphisms [298]; and in genome-wide association studies, the
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gene KO) was accompanied by reduced degradation of insulin and
higher levels of Aβ in the brain [300]. Moreover, the neuron-speciﬁc ec-
topic expression of IDE in a mouse model for AD (APPSwe/Ind) [301]
was sufﬁcient to relieve the burden of amyloid plaque-related patholo-
gy [302]. Consequently, the upregulation of IDE activity has been amply
suggested for therapeutic purposes. However, it has to be stressed that
the occurrence of IDE in various subcellular compartments renders the
attribution of speciﬁc contributions of IDE functions to one location
like peroxisomes rather difﬁcult.
6.4. Peroxisomes and other neurological diseases
In recent years, with increasing progress in lipidomic techniques,
changes in the amounts of plasmalogens either in the brain or in the
periphery have been described in a variety of neurological diseases.
These include Parkinson's disease [303], schizophrenia [304,305],
Down syndrome [306,307], Pelizaeus–Merzbacher disease [308], and
lysosomal storage disorders like Gaucher's disease [309] or neuronal
ceroid lipofuscinosis [310]. However, inmany cases the detected chang-
es might be too small to be physiologically relevant and are likely to be
counteracted by compensatory lipid changes [232]. Additionally,
changes of plasmalogen levels may be secondary to the plethora of
degenerative and pathologic processes in these diseases. Special caution
is warranted for the interpretation of altered levels of plasmalogens in
peripheral blood, as even in the milder forms of peroxisomal disorders
some cases are known with normal plasmalogen levels in plasma (see
Section 5.1.1.). Therefore, only limited conclusions about pathology
can be drawn from these values; this can also be deduced from the ob-
servation that lipid levels in blood and brain in disease often correlate
poorly [311].
It should be noted in the context of peroxisomes and neurodegener-
ative disorders that in all three Zellwegermousemodels (Pex2, Pex5 and
Pex13 deﬁciency [60–62]), increased α-synuclein oligomerization was
observed in brain tissues [312]. This is of particular interest, as in
Parkinson's disease and related synucleinopathies, the normally
presynaptic protein α-synuclein aggregates intraneuronally to form
Lewy bodies, the neuropathological hallmark of these diseases. When
α-synuclein was overexpressed in murine ﬁbroblasts, the oligomeriza-
tion and phosphorylation of α-synuclein was markedly higher in
Pex5-deﬁcient cells than in control ﬁbroblasts [312]. In this study, it
was suggested thatα-synuclein oligomerization and aggregation corre-
latewith lipid alterations rather thanwithmitochondrial dysfunction or
oxidative stress.
Based on the observations that inmurine experimental autoimmune
encephalomyelitis (EAE) several peroxisomal functions appear to be
impaired [313] and that peroxisome deﬁciency goes along with severe
neuroinﬂammation, a contribution of peroxisomal dysfunction to the
pathology in multiple sclerosis, a chronic inﬂammatory demyelinating
disease of the CNS, was postulated [314]. Gray and coworkers further
supported their hypothesis by showing decreased expression of
ABCD3mRNA together with a reduction of ABCD3/PMP70 immunoreac-
tivity in gray matter within and outside of lesions, as well as a slight
elevation of VLCFA levels in post mortem cortical gray matter from MS
patients [314]. Contrary to the idea of a general impairment of
peroxisomal functions, the results of a recent report indicate a tendency
towards increased plasmalogen levels in the serum of multiple sclerosis
patients [315]. However, as discussed above, peripheral lipid levels may
be of limited relevance for the interpretation of pathological processes
in the brain.
7. Concluding remarks
The functionality of the nervous system critically depends on the
ability of peroxisomes to provide biosynthetic intermediates and to de-
grade undesired compounds that interfere with brain formation, brainfunction or brain preservation. Moreover, peroxisomes participate in
themaintenance ofmetabolites in the appropriate concentration ranges
(e.g., D-amino acid or ROS levels). A lack of each of these functions
causes structural abnormalities of the brain, in particular in the cortex
or the cerebellum, defects in the intercellular communication of
neurons affecting electrical propagation rates along the axon and synap-
tic transmission efﬁciency or inappropriate onset of aging and inﬂam-
matory processes.
The spectrum of neurological symptoms observed in patients suffer-
ing from PBD or single enzyme and transporter deﬁciencies is surpris-
ingly broad. This variability can be traced back to: (i) residual activity
of the affected protein causingmilder pathologies (PBD), (ii) the genetic
background of patients rendering themmore susceptible or resilient, or
(iii) environmental factors ranging from disease-inducing occurrences
to protection by nutrition deprived of detrimental compounds (Refsum
disease). This implies that patients with mild variants of PBD might
even escape correct diagnosis. Moreover, the observations that peroxi-
somes tightly interact with other organelles and that peroxisomal dys-
function secondarily affects their functionality suggest that patients
suffering from inherited diseases originating from peroxisomes may
beneﬁt from therapeutic approaches targeting such secondary sites.
Finally, increasing evidence indicates that peroxisomes also exert a
modulatory role in more common neurodegenerative disease such as
AD, autism, ALS or schizophrenia. This is partially supported by linkage
analyses, but also by comparative measurements of enzymatic
activities, expression levels of mRNAs or proteins or changes in metab-
olite concentrations linked to peroxisomal functions between cohorts of
patients and healthy controls. Future work applying steadily improving
bioanalytical tools will help to decipher the relationship between the
accumulation or deprivation of biomolecules linked to peroxisomes
(e.g., DHA, plasmalogens or D-amino acids) and certain physiological
or pathophysiological conditions.
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